key: cord-0821364-1y15wmjg authors: Fujino, Takahisa; Nomoto, Hidetoshi; Kutsuna, Satoshi; Ujiie, Mugen; Suzuki, Tetsuya; Sato, Rubuna; Fujimoto, Tsuguto; Kuroda, Makoto; Wakita, Takaji; Ohmagari, Norio title: Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan date: 2021-04-03 journal: Emerg Infect Dis DOI: 10.3201/eid2704.210138 sha: 12943e23601c5a69af815b2e29461f7579d87c31 doc_id: 821364 cord_uid: 1y15wmjg Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with higher transmission potential have been emerging globally, including SARS-CoV-2 variants from the United Kingdom and South Africa. We report 4 travelers from Brazil to Japan in January 2021 infected with a novel SARS-CoV-2 variant with an additional set of mutations. Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with higher transmission potential have been emerging globally, including SARS-CoV-2 variants from the United Kingdom and South Africa. We report 4 travelers from Brazil to Japan in January 2021 infected with a novel SARS-CoV-2 variant with an additional set of mutations. C oronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1), has wreaked havoc worldwide. SARS-CoV-2 causes severe respiratory failure, often rapidly in susceptible patients. Moreover, new variants with estimated higher transmission rates have begun circulating globally, such as Variant of Concern 202012/01 (VOC-202012/01) from the United Kingdom and variant 501Y.V2 from South Africa (2) . The virulence, reinfection potential, antibody response to, and efficacy of vaccines against these strains, are still unknown, posing a risk for future pandemics. We detected a previously unreported SARS-CoV-2 variant strain in a family arriving in Japan from Brazil. On January 2, 2021, a healthy man in his 40s arrived at Haneda Airport, Tokyo, Japan, from Amazonas state in Brazil via Istanbul, Turkey. At the airport quarantine station, he and the 3 family members traveling with him tested positive for SARS-CoV-2 by quantitative real-time reverse transcription PCR. All 4 were asymptomatic and were accommodated in a government-designated quarantine facility to wait out the required 14-day quarantine. On day 2 of their visit, a fever of 37.6°C developed in the man; on day 4, the man had a cough. On day 6, his oxygen saturation (SpO 2 ) dropped to 93% on ambient air, and he was transferred to the National Center for Global Health and Medicine, a tertiary care hospital in Tokyo, for respiratory failure. The remaining 3 family members remained asymptomatic and continued to stay at the governmentdesignated accommodation. At admission, the patient had a cough and mild malaise. Physical examination was almost normal except for late inspiratory crackles in the bilateral lower lung fields. The patient's body temperature was 37.4°C; blood pressure was 113/69 mm Hg and pulse rate 108 beats/min. The patient had a regular respiratory rate of 18 breaths/min and an SpO 2 of 93% on ambient air. Laboratory tests showed a high C-reactive protein level of 10.47 mg/dL (reference range 0.00-0.14 mg/dL), but complete blood counts, renal function, liver function, and coagulation tests all were within reference ranges. Chest radiography and computed tomography showed ground-glass opacities in the lower lobes of both lungs. We started the patient on treatment with 200 mg remdesivir, a subcutaneous injection of unfractionated heparin, and 6 mg oral dexamethasone on day 1 of admission. On day 2 of admission, the patient's fever subsided, and his general condition improved marginally. On day 3, oxygen therapy was not needed, blood tests showed a decrease in C-reactive protein levels, and no adverse side effects of treatment were observed. He continued treatment with 100 mg/d remdesivir and unfractionated heparin until day 5 of admission and dexamethasone until day 7, during which time we observed no flare-up of symptoms. We subjected the SARS-CoV-2 detected in the case-patient and in his family to whole-genome sequencing. Phylogenetic analysis suggested a novel variant (GISAID [https://www.gisaid.org] reference no. EPI_ISL_792681) belonging to pangolin lineage P.1 with 12 nonsynonymous mutations including K417T, E484K, and N501Y in the receptorbinding domain of the spike protein (N.R. Faria et al., unpub data, https://virological.org/t/genomiccharacterisation-of-an-emergent-sars-cov-2-lineagein-manaus-preliminary-findings/586). In addition, the variant strain we detected in the travelers had the N501Y mutation in the receptor-binding site of the spike protein, as noted in VOC-202012/01 and 501Y.V2, and the E484K mutation, similar to that noted in the 501Y strain. We did not observe any remarkable difference in the clinical course of this case-patient compared with COVID-19 cases caused by other known SARS-CoV-2 strains. According to multiple modeling analyses, the new VOC-202012/01 variant could be more infectious than previous strains and might have <70% increased transmissibility (3) (4) (5) . Moreover, PCR testing and genomic analysis for this strain suggested an increased viral load in VOC-202012/01 variant. Another strain, 501Y.V2 from South Africa, also has been suggested to have increased transmissibility (H. Tegally et al., unpub. data, https://doi.or g/10.1101/2020.12.21.20248640). However, to date, no definitive evidence has shown that either VOC-202012/01 or 501Y.V2 are associated with more severe COVID-19 cases. The symptoms in this patient were relatively mild, although short-term oxygen administration was necessary. Onset of pneumonia a week after the onset of disease also followed the conventional clinical course. However, because the patient was young and had no underlying conditions, this case cannot be generalized. In conclusion, we identified a novel variant strain of SARS-CoV-2 in 4 travelers from Brazil. Variant strains are appearing across the world now, and quarantine systems need to be strengthened. We hope to elucidate the infectivity, pathogenicity, and relationship of SARS-CoV-2 variants to vaccines while continuing to take conventional precautions against novel variant strains. Spanish Working Group on MDR-TB. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain Human tuberculosis due to Mycobacterium bovis and M. caprae in Spain Tuberculosis due to Mycobacterium bovis and Mycobacterium caprae in sheep Transmission of tuberculosis caused by Mycobacterium caprae between dairy sheep and goats Assessment of BCG and inactivated Mycobacterium bovis vaccines in an experimental tuberculosis infection model in sheep Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene Drug susceptibility of Spanish Mycobacterium tuberculosis complex isolates from animals Human Mycobacterium bovis infection in Castile and Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis References 1. World Health Organization. Coronavirus disease (COVID-19) situation reports. Weekly epidemiological update-19 World Health Organization. SARS-CoV-2 variant European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom NERVTAG meeting on SARS-CoV-2 variant under investigation VUI-202012/01 Note of meeting Tokyo 162-8655, Japan; email: sonare.since1192@gmail.com Isolation of Rickettsia rickettsii in Rocky Mountain Spotted Fever Outbreak R ocky Mountain spotted fever (RMSF) causes severe cases of rickettsiosis and is considered a principal tickborne pathogen in the Americas (1) The patients reported no history of recent tick bites or attachment; according to each patient, the duration of symptoms varied from 9 to 11 days. Of these 7 patients, 2 recovered after treatment with doxycycline, 1 recovered without treatment with doxycycline, and 4 died. We diagnosed rickettsiosis by PCR on blood and samples of spleen, liver, brain and lung, using the We report new cases of Rocky Mountain We thank Tsuyoshi Sekizuka, Kentaro Itokawa, Masanori Hashino, Nozomu Hanaoka, Nobuo Koizumi, and Tsuguto Fujimoto for assistance with PCR testing and whole-genome sequencing, and we thank the clinical staff at the National Center for Global Health and Medicine for their dedicated clinical practice and patient care. Dr. Fujino is a physician at the National Center for Global Health and Medicine in Shinjuku-ku, Tokyo, Japan. His main research interest is hematology.